168 related articles for article (PubMed ID: 30943133)
21. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.
Guignard S; Gossec L; Salliot C; Ruyssen-Witrand A; Luc M; Duclos M; Dougados M
Ann Rheum Dis; 2006 Dec; 65(12):1631-4. PubMed ID: 16901960
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
23. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
Cantini F; Niccoli L; Goletti D
J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
[TBL] [Abstract][Full Text] [Related]
25. Certolizumab pegol in the treatment of Crohn's disease.
Ferrante M; Vermeire S; Rutgeerts P
Expert Opin Biol Ther; 2013 Apr; 13(4):595-605. PubMed ID: 23451881
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
[TBL] [Abstract][Full Text] [Related]
27. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
28. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
29. The Efficacy of Golimumab Against Non-Infectious Uveitis: A PRISMA-Compliant Systematic Review and Meta-Analysis.
Okada K; Zhou Y; Hashida N; Takagi T; Tian YS
Ocul Immunol Inflamm; 2023 Jul; 31(5):1013-1023. PubMed ID: 35771679
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis.
Yazgan S; Celik U; Işık M; Yeşil NK; Baki AE; Şahin H; Gencer E; Doğan İ
Int Ophthalmol; 2017 Feb; 37(1):139-145. PubMed ID: 27154720
[TBL] [Abstract][Full Text] [Related]
31. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.
Calvo-Río V; Blanco R; Santos-Gómez M; Rubio-Romero E; Cordero-Coma M; Gallego-Flores A; Veroz R; Torre I; Hernández FF; Atanes A; Loricera J; González-Vela MC; Palmou N; Hernández JL; González-Gay MA
Semin Arthritis Rheum; 2016 Aug; 46(1):95-101. PubMed ID: 27060872
[TBL] [Abstract][Full Text] [Related]
32. Certolizumab pegol - Tumor necrosis factor inhibitor for refractory uveitis.
Sharon Y; Chu DS
Am J Ophthalmol Case Rep; 2020 Jun; 18():100633. PubMed ID: 32190782
[TBL] [Abstract][Full Text] [Related]
33. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
34. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.
van der Horst-Bruinsma IE; van Bentum RE; Verbraak FD; Deodhar A; Rath T; Hoepken B; Irvin-Sellers O; Thomas K; Bauer L; Rudwaleit M
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211003803. PubMed ID: 33854572
[TBL] [Abstract][Full Text] [Related]
35. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
36. The current status of biological treatment for uveitis.
Gaggiano C; Sota J; Gentileschi S; Caggiano V; Grosso S; Tosi GM; Frediani B; Cantarini L; Fabiani C
Expert Rev Clin Immunol; 2020 Aug; 16(8):787-811. PubMed ID: 32700605
[TBL] [Abstract][Full Text] [Related]
37. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
39. Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris.
Yamaguchi K; Hayashi T; Takahashi G; Momose M; Asahina A; Nakano T
Case Rep Ophthalmol; 2018; 9(3):499-503. PubMed ID: 30687070
[TBL] [Abstract][Full Text] [Related]
40. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
